Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Daiichi Sankyo
Chinese Patent Office
Dow
Cipla
Medtronic
QuintilesIMS
Argus Health
Cerilliant
Healthtrust

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,899,717

« Back to Dashboard

Which drugs does patent 6,899,717 protect, and when does it expire?

Patent 6,899,717 protects OZURDEX and is included in one NDA.

This patent has thirty-two patent family members in seventeen countries.
Summary for Patent: 6,899,717
Title: Methods and apparatus for delivery of ocular implants
Abstract:An apparatus and methods for delivering ocular implants or microimplants. The apparatus is ergonomically designed for ease of use, and a simple manual depression of an actuator produces proportional movement of a linkage causing the implant or microimplant to be ejected through a cannula disposed at the desired location in the eye. Small gauge cannulas are provided for self-sealing methods of delivery.
Inventor(s): Weber; David (Danville, CA), Kane; Ingrid (Los Altos, CA), Rehal; Mike (Boulder Creek, CA), Lathrop, III; Robert L. (Santa Clara, CA), Aptekarev; Kenny (Santa Cruz, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:10/246,884
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

Drugs Protected by US Patent 6,899,717

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,899,717

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,090,681 Methods and apparatus for delivery of ocular implants ➤ Try a Free Trial
7,753,916 Methods and apparatus for delivery of ocular implants ➤ Try a Free Trial
7,147,644 Apparatus for delivery of ocular implants ➤ Try a Free Trial
7,468,065 Apparatus for delivery of ocular implants ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,899,717

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I369975 ➤ Try a Free Trial
Taiwan 200635565 ➤ Try a Free Trial
Taiwan I282271 ➤ Try a Free Trial
Taiwan 200507819 ➤ Try a Free Trial
Russian Federation 2294722 ➤ Try a Free Trial
Russian Federation 2005108563 ➤ Try a Free Trial
Poland 413351 ➤ Try a Free Trial
Poland 223153 ➤ Try a Free Trial
Poland 376478 ➤ Try a Free Trial
New Zealand 553891 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Farmers Insurance
Julphar
Cerilliant
McKesson
Merck
Federal Trade Commission
US Department of Justice
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot